All In Biotech

Drug Trial Radar · NCT03531905

Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C

A Randomized Study to Evaluate the Efficacy and Safety of Bempedoic Acid 180 + Ezetimibe 10 Fixed-Dose Combination Compared to Ezetimibe and Placebo In Subjects With T2DM and Elevated LDL-Cholesterol

Last checked: Nov 19, 2026Latest source record: Apr 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 242 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

242

Actual

Start

May 9, 2018

Primary completion

Jun 18, 2019

Study completion Jun 18, 2019

Sponsor

Lead sponsor
Esperion Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
May 22, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Factorial
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

12 week study to assess the LDL-C lowering efficacy, other lipid and glycemic measures, and safety of bempedoic acid/ezetimibe FDC compared to ezetimibe and placebo in patients with type 2 diabetes (T2D) and elevated LDL-C

Conditions

  • Diabetes
  • Diabetes Mellitus, Type 2
  • Cholesterolemia

Interventions

  • Bempedoic acid + Ezetimibe FDC Oral TabletDrug

    Experimental therapy of bempedoic acid 180 mg + ezetimibe 10 mg FDC tablet

  • Ezetimibe 10 mg Oral TabletDrug

    Ezetimibe 10 mg tablet, overencapsulated for blinding purposes

  • Placebo Oral TabletDrug

    Placebo tablet, matched for the FDC product for blinding purposes

  • Placebo oral capsuleDrug

    Placebo over-encapsulated for blinding purposes

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline to Week 12/End of Study (EOS) in Low-density Lipoprotein Cholesterol (LDL-C)Time frame: Baseline; Week 12

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Trials Research

    Lincoln, California

  • FInlay Medical Research

    Miami, Florida

  • L-MARC Research Center

    Louisville, Kentucky

  • Hampton Roads Center for Clinical Research

    Suffolk, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.